

# INPLASY

## NiuHuangNingGongPian (Traditional Chinese medicine) for schizophrenia (Review)

INPLASY2023110060

doi: 10.37766/inplasy2023.11.0060

Received: 15 November 2023

Published: 15 November 2023

### Corresponding author:

Rongchao Li

lirongchao163@163.com

### Author Affiliation:

Peking University School of Continuing Medical Education.

Li, RC<sup>1</sup>.

### ADMINISTRATIVE INFORMATION

**Support** - 25163.

**Review Stage at time of this submission** - Preliminary searches.

**Conflicts of interest** - None declared.

**INPLASY registration number:** INPLASY2023110060

**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 15 November 2023 and was last updated on 15 November 2023.

### INTRODUCTION

**Review question / Objective** The purpose of this study is to investigate the difference in efficacy and safety between NiuHuangNingGongPian combined with antipsychotic drugs and antipsychotic drugs alone in the treatment of schizophrenia. The selected research method is the RCT experiment; P: schizophrenia; I: NiuHuangNingGongPian (Traditional Chinese medicine) and antipsychotic; C: antipsychotic; O: efficacy and safety; S: RCT.

**Condition being studied** Schizophrenia.

### METHODS

**Participant or population** Patients with schizophrenia.

**Intervention** NiuHuangNingGongPian combined with antipsychotic drugs.

**Comparator** antipsychotic drugs alone.

**Study designs to be included** RCT.

**Eligibility criteria** schizophrenia CCMD-3 , ICD-10.

**Information sources** CNKI, CBM, PubMed.

**Main outcome(s)** Global state: Clinically important change; Mental state: Average total endpoint PANSS score; Adverse effects: Movement disorders; Adverse effects: Metabolic weight change.

**Quality assessment / Risk of bias analysis** The Cochrane Collaboration's tool.

---

**Strategy of data synthesis** STATA software conducts data synthesis. If  $P > 0.10$  or  $I^2 \leq 50\%$ , the heterogeneity is considered to have no statistical significance and fixed-effect models (FEM) will be performed. If  $P > 50\%$ , the heterogeneity is considered to have statistically significant and random-effect models (REM) will be performed.

**Subgroup analysis** We proposed to undertake this review and provide an overview of the effects of NiuHuangNingGongPian (Traditional Chinese medicine) for people with schizophrenia in general. No subgroup analyses were anticipated.

**Sensitivity analysis** STATA software conducts sensitivity analysis: to reflect the sensitivity of a particular article by examining the changes in the effect size after deleting the article.

**Country(ies) involved** China.

**Keywords** NiuHuangNingGongPian schizophrenia efficacy safety.

**Contributions of each author**

Author 1 - Rongchao Li.

Email: [lirongchao163@163.com](mailto:lirongchao163@163.com)